ArticleClinical neuroradiology2026
RCBVmax from DSC Perfusion MRI as a Supportive Imaging Biomarker for Differentiating IDH-Mutant Astrocytomas and Oligodendroglioma.
Article in Clinical neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGliomas, particularly astrocytomas (IDH-mutated, 1p/19q intact) and oligodendrogliomas (IDH-mutated, 1p/19q co-deleted), differ significantly in their clinical behavior and prognosis. Accurate differentiation between these subtypes is crucial for guiding therapeutic decisions. Non-invasive imaging biomarkers, such as T2-Flair mismatch sign and relative cerebral blood volume (rCBV), have shown promise in glioma classification.
methodsThis retrospective multicenter study analyzed 42 patients with astrocytoma and 21 with oligodendroglioma. Demographic, histopathological, and imaging data were collected, with a focus on rCBV parameters derived from dynamic susceptibility contrast perfusion MRI. Statistical analyses were conducted to assess differences between the groups and evaluate the discriminatory power of rCBV metrics. After correction for multiple corrections, level of significance was set at p < 0.01.
resultsPatients with astrocytoma and oligodendroglioma were similar in age and gender distribution (mean age and male-female-ratio; p = 0.01 respectively p = 0.04). The rCBVmax value was significantly higher in oligodendrogliomas (11.64 vs. 7.69, p < 0.001) and demonstrated a good discriminatory power (AUC = 0.764). Median and mean rCBV values showed non-significant differences between oligodendroglioma and astrocytoma (p = 0.02 respectively p = 0.03).
conclusionrCBVmax emerges as a potential imaging marker for differentiating oligodendrogliomas from astrocytomas. These findings can be explained by biological properties of oligodendrogliomas and thereby underscore the potential of advanced imaging techniques in non-invasive glioma classification. However, larger prospective studies are required to validate these results and standardize imaging protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.